3.04
-0.11(-3.49%)
Currency In USD
Address
141 Portland Street
Cambridge, MA 02139
United States of America
Phone
617 337 4680
Website
Sector
Healthcare
Industry
Biotechnology
Employees
88
First IPO Date
January 26, 2018
| Name | Title | Pay | Year Born |
| Mr. Ilan Ganot | Co-founder, Strategic Advisor to the Chief Executive Officer & Director | 847,867 | 1974 |
| Mr. Alexander G. Cumbo | President, Chief Executive Officer & Director | 918,550 | 1971 |
| Mr. Ian F. Smith A.C.A., C.P.A. | Executive Chair | 75,000 | 1966 |
| Mr. Kevin Tan C.F.A. | Chief Financial Officer & Treasurer | 607,181 | 1978 |
| Mr. David Tyronne Howton Jr., J.D. | Chief Operating Officer, General Counsel & Secretary | 648,880 | 1972 |
| Ms. Annie Ganot | Co-Founder & Head of Patient Advocacy | 0 | N/A |
| Mr. Paul Herzich | Chief Technology Officer | 0 | 1978 |
| Dr. Jessie Hanrahan Ph.D. | Chief Regulatory Officer | 0 | 1976 |
| Dr. Shuli Kulak M.D. | Head of Corporate Strategy & Business Development | 0 | N/A |
| Ms. Allison Bogosian J.D. | Senior Vice President of Human Resources | 0 | N/A |
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.